Board summary
Key figures
47,203
Registered population
60.8% aged 18–64
19.9%
Aged 65+
ICB 19.0% · England 17.9%
3.5%
Ethnic minority (non-White)
1.4% Asian · England 9.6%
32.2%
In IMD quintile 1
ICB 31.9% · England 21.0%
~15,916
Core20 residents (est.)
Resident basis; registered basis ~15,370 · see page 3
8,483
Hypertension register
+3.49% in 3 yrs · England +5.60%
505
SMI register
22.2% of St. Helens (LAD)'s
1,434
COPD register
Reviews -8.95% in 3 yrs
Forecast to 2030
9,247
Hypertension patients, 2034
+764 on today
62.0%
QRISK ≥20% on statins, 2034
+0.24pp over 3 yrs
4.9%
Cancer prevalence, 2034
England 4.5%
Three things the board should see
Asthma annual reviews lag all comparators.
Only 52.2% of asthma patients had a review (England 65.7%, ICB 62.3%), leaving about 1,700 unreviewed, which may reflect recall gaps.
Heart failure reviews fell over three years.
Heart failure reviews fell 23.2% over 2023 to 2025 (England +8.7%) to 61.4% (England 78.5%), which could reflect review capacity constraints.
First-dose MMR exceeds the national target.
At age 5, first-dose MMR reaches 96.3% (England 91.7%, target 95.0%), though second-dose uptake is 6.5 pp lower at 89.8%.
Population, age and ethnicity
Older patients make up 19.9% of the list, exceeding England's 17.9%
Newton and Haydock PCN serves 47,203 registered patients across four practices. Patients aged 65+ comprise 19.9% (9,413 patients), compared with 20.1% in St. Helens (LAD), 19.0% in NHS Cheshire and Merseyside ICB and 17.9% in England. Those aged 0-17 represent 19.3% (LAD 18.7%, ICB 19.2%, England 19.6%). Based on Census usual residents rather than GP lists, 96.5% are White (LAD 96.5%, ICB 93.0%, England 81.1%), leaving a 3.5% ethnic minority share. Unverified population projections forecast 1.6% growth to 2030 (LAD 1.6%, ICB 2.3%, England 2.3%), informing primary care capacity planning.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are St. Helens (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (St. Helens LA) | 2,208 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 51.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (St. Helens LA) | 1,143 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (St. Helens LA) | 24.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 32.2% across the PCN, with all four practices exceeding England
The PCN Core20 cohort is 32.2%, above England (21.0%) and the ICB (31.9%), though below St. Helens (38.5%). Weighted practice share is 32.6%, reflecting differing practice and resident bases. All four practices exceed England. By concentration, Modality St Helens leads at 37.7% (6,293 estimated patients), followed by Newton Practice at 34.0% (3,536) and Vista Road Surgery at 28.5% (2,444). By volume, Patterdale Lodge Med Ctre has 3,097 patients despite a 26.8% share. Inequalities planning requires balancing high-volume lists alongside concentrated deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
505
SMI register
1.05% recorded prevalence
220
Learning disability register
0.46% recorded prevalence
14
Care homes, 546 beds
In the PCN catchment
11.7%
Provide unpaid care
St. Helens (LAD), Census 2021
The PCN records 505 severe mental illness patients (1.1%, England 1.0%) and 220 on the learning disability register (0.5%, England 0.6%). Catchment services include 14 care homes with 546 beds. St. Helens borough recorded 20 rough sleepers in 2025 and an 11.7% unpaid care rate, which cannot be extrapolated to the PCN. Lower recorded learning disability prevalence may reflect diagnostic or recording variation; clinical register audits would test this.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.1% (505 patients). Published check elements show 80.1% had a blood pressure check (England 83.4%) and 76.7% had BMI recorded (England 82.1%). Lagging national rates may leave physical health risks unmonitored.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,483
Hypertension register
+3.49%
Register growth, 3 yrs
St. Helens (LAD) +5.27% · England +5.60%
+1.13pp
BP control, under 80
≤140/90 · −2.86pp aged 80+
+764
More patients by 2030
Forecast 9,247 (18.85%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.6% (8,483 patients), below St. Helens (18.7%) but above the ICB (16.8%) and England (15.2%), while three-year register growth of +3.5% trailed England (+5.6%). For monitoring, 86.3% had a recent blood pressure check (England 90.0%). Blood pressure control for patients under 80 is 63.2%, trailing St. Helens (65.9%), the ICB (66.4%) and England (67.8%). For patients aged 80 and over, control fell 2.9 pp over three years (England +1.8 pp) to 79.3% (England 81.2%). Across all ages, treatment to target is 66.2% (England 70.3%). Lower blood pressure control than comparators across age groups could reflect recall or titration gaps to evaluate locally.
Lipids and statins
Lipid therapy for QRISK ≥ 20% is 61.5% (St. Helens 62.1%, ICB 63.2%, England 63.6%), with three-year growth of +0.4% trailing England (+6.2%). CKD coverage is 68.2% (England 70.3%). Lower coverage than national rates may reflect opportunities to review high-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 102,360 | £1.30 | £1.71 | £1.86 | £133,068 |
| Cardiovascular (all), 2025 | 146,115 | £3.82 | £4.37 | £3.33 | £558,159 |
In 2026, the PCN prescribed 102,360 lipid-regulating items at £1.30 per item, below St. Helens (£1.75), the ICB (£1.71) and England (£1.86), amounting to £57,322 less than at England's unit cost, across 102,360 items. Lower unit expenditure per item than comparators provides contextual cost context for prescribing discussions.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.27%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.45%
Asthma prevalence, PCN 3-yr % change
Asthma recorded prevalence is 8.0% (3,624 patients), above England's 6.6% and ICB's 7.0%, yet 12-month reviews reach only 52.2% (England 65.7%, ICB 62.3%), leaving about 1,700 patients unreviewed. Prescribing of asthma management items for ages 5-19 is 2,740 per 1,000 (England 1,488). COPD prevalence is 3.0% (1,434 patients; England 1.9%), but reviews fell 8.9% over 2023 to 2025 (England +2.8%) to 70.2% (England 76.4%). High disease prevalence combined with lagging annual reviews may indicate review capacity constraints, unverified locally.
Cancer register and children's immunisation
Cancer register prevalence is 4.1% (1,966 patients; England 3.8%). In Q1 2025/26 childhood immunisations, PCN coverage exceeds England, but a dose contrast emerges: MMR dose 1 at age 5 achieves 96.3% (England 91.7%, cohort 108), whereas MMR dose 2 drops to 89.8% (England 82.8%), a 6.5 pp drop below dose 1 and 5.2 pp below the 95.0% target. Slower second-dose uptake could reflect recall attrition, unverified locally.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%), with known stage recorded for 72.8% (13,490 of 18,522). This represents a 2.6 pp increase from 52.8% in 2013, though reaching the 75.0% national ambition would require about 2,640 extra early diagnoses annually across the ICB. ICB stage data reflects system pathways rather than PCN delivery. Locally, PCN cervical screening coverage is 69.1% (England 66.8%), but Modality St Helens records 62.9%. Practice-level screening variation could delay earlier cancer detection for registered patients.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Mersey and West Lancashire Teaching Hospitals NHS Trust achieved 78.0% on the 62-day cancer standard, exceeding the ICB (76.2%) and England (71.2%), but below North Cheshire and Mersey NHS Foundation Trust (83.7%). On the 28-day faster diagnosis standard, the trust achieved 72.4% against the 75.0% standard, trailing the ICB (77.2%) and England (79.3%). For 6+ week diagnostic waits, non-obstetric ultrasound was 23.3% (England 19.6%) and colonoscopy was 18.0% (England 30.8%). These provider waiting times reflect wider system performance rather than PCN delivery.
| Pathways within standard (%) | Mersey and West Lancashire | North Cheshire and Mersey | Wrightington, Wigan and Leigh | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 80.21 | 82.80 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 98.17 | 89.04 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 83.67 | 76.78 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | North Cheshire and Mersey | Wrightington, Wigan and Leigh | England |
|---|---|---|---|---|
| MRI | 14.04 | 0.53 | 0.49 | 21.40 |
| CT | 13.08 | 2.32 | 7.78 | 9.92 |
| Echocardiography | 34.88 | 28.04 | 24.37 | 28.48 |
| Colonoscopy | 18.04 | 15.98 | 6.10 | 30.83 |
| Gastroscopy | 18.17 | 20.24 | 12.54 | 29.02 |
| All 15 DM01 tests | 21.17 | 6.34 | 14.36 | 23.14 |
| Community services activity | St. Helens residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 48,525 | 541,280 |
| Referrals | 7,815 | 97,150 |
| Patients with a contact | 12,745 | 146,240 |
Community services (residents of St. Helens), Jun 2026 (provisional). In June 2026 (provisional), St. Helens borough residents recorded 48,525 community service contacts, with 29,090 among adults aged 65 and over (59.9% of contacts). These figures reflect borough resident utilisation rather than PCN provision, indicating substantial community activity among older people across the wider local authority.
Practice variation and patient experience
Practice telephone access spans 36.8 pp, with two practices trailing England
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Patterdale Lodge | 106 | 26.8 | 60.8% | 67.7% | 78.5% |
| Vista Road Surgery | 103 | 28.5 | 63.5% | 75.5% | 73.4% |
| Modality St Helens | 110 | 37.7 | 26.6% | 75.2% | 63.4% |
| Newton Practice | 93 | 34.0 | 35.4% | 67.3% | 62.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Heart failure reviews fell 23.2% over 2023 to 2025 against England's +8.7%
Over 2023 to 2025, heart failure reviews fell 23.2% (England +8.7%), dementia prevalence fell 13.7% (England +6.0%), and COPD reviews fell 8.9% (England +2.8%). In contrast, cervical screening rose +0.5% (England -1.0%) and diabetes HbA1c control rose +4.8% (England +4.4%). Currently, heart failure reviews stand at 61.4% against England's 78.5% and St. Helens (LAD) 73.1%. Slower review activity could reflect review capacity or recall pressures, which local practice audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
COPD reviews
Alcohol record (psychosis)
BMI record (SMI)
Cervical screening
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | St. Helens (LAD) | Asset | PCN | St. Helens (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 14 (546 beds) | n/a | Schools (catchment) | 57 | n/a |
| Children's centres | 3 | 8 | Places of worship | 34 | 90 |
| Libraries | 5 | 15 | Primary schools (LA maintained) | 8 | 32 |
| Primary academies | 4 | 11 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma reviews reach 52.2% of 3,624 patients, below St. Helens (58.2%), the ICB (62.3%) and England (65.7%), leaving 1,733 (about 1,700) unreviewed. For discussion: the PCN could trial a single recall template, offer flexible after-school or holiday slots, and review inhaler prescribing during annual reviews. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR second-dose recall
In Q1 2025/26 (cohort 108), age-5 MMR coverage is 96.3% for dose 1 (England 91.7%) vs 89.8% for dose 2 (England 82.8%), a 6.5 pp gap (5.2 pp below the 95.0% target). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Learning disability register validation
Recorded learning disability prevalence is 0.5% (220 of 47,203 patients), below the 0.6% in St. Helens, the ICB and England, a benchmark gap range of +45 to +57. For discussion: practices could audit clinical codes, validate registers against social-care records where data sharing exists, and send accessible annual check invitations. Moderate effort to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register review (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control and recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| MMR second dose recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Practice telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR second-dose recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
